- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05551741
A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)
A First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Dalia Bracha
- Phone Number: +972547831876
- Email: dalia@immunobrain.com
Study Contact Backup
- Name: Kinga Barsony
- Email: kinga.barsony@worldwide.com
Study Locations
-
-
-
Ashkelon, Israel
- Recruiting
- Barzilai Medical Center
-
Contact:
- Vered Loew Shavit
- Phone Number: +97286745117
-
Haifa, Israel
- Recruiting
- Rambam Health Care Campus
-
Contact:
- Merav Shor
- Phone Number: +972-50-7773471
- Email: m_shor@rambam.health.gov.il
-
Petach Tikva, Israel
- Recruiting
- Rabin Medical Center
-
Contact:
- Sara Mola
- Email: Saramol@clalit.org.il
-
Ramat Gan, Israel
- Recruiting
- Sheba Medical Center
-
Contact:
- Efrat Tal
- Phone Number: +972-54-6881186
- Email: Efrat.Tal@sheba.health.gov.il
-
Tel Aviv, Israel
- Recruiting
- Tel-Aviv Sourasky Medical Center
-
Contact:
- Noa Trablus
- Phone Number: +972-54-7324473
- Email: noat@tlvmc.gov.il
-
-
-
-
-
Amsterdam, Netherlands
- Recruiting
- Brain Research Center
-
Contact:
- Jort Vijverberg
- Email: info@brainresearchcenter.nl
-
Contact:
- Phone Number: +31203017170
-
-
-
-
-
Bath, United Kingdom, BA1 3NG
- Recruiting
- RICE - Research Institute for the Care of Older People
-
Contact:
- Nicola Youlden
- Phone Number: +44 (0)1225476420
- Email: ny247@bath.ac.uk
-
London, United Kingdom
- Recruiting
- Sheffield teaching Hospitals NHS Trust
-
Contact:
- Daisy Priest
- Phone Number: +44-114 22 65580
- Email: Daisy.priest1@nhs.net
-
London, United Kingdom
- Recruiting
- Dementia Research Centre, National Hospital for Neurology and Neurosurgery
-
Contact:
- Marivic Ricamara
- Email: Marivic.ricamara@nhs.net
-
Contact:
- Miguel Paz-Alvarez
- Email: miguel.paz-alvarez@nhs.net
-
Principal Investigator:
- Catherine Mummery, MD PhD FRCP
-
London, United Kingdom, SE5 8AF
- Recruiting
- King's College London - Institute of Psychiatry, Psychology & Neuroscience (IoPPN)
-
Contact:
- Miguel Vasconcelos Da Silva
- Phone Number: 02078480024
-
Contact:
- Email: miguel.1.dasilva@kcl.ac.uk
-
-
Hampshire
-
Southampton, Hampshire, United Kingdom
- Recruiting
- University Hospital Southampton NHS Foundation Trust
-
Contact:
- Christopher Kipps
- Phone Number: 02381204989
- Email: Christopher.kipps@uhs.nhs.uk
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of early Alzheimer's disease based on the National Institute on Aging and Alzheimer's Association) (NIA-AA Research Framework criteria, regardless of apolipoprotein E (APOE) gene status.
- Able to speak, read and write the local language fluently.
- With respect to symptomatic treatment for Alzheimer's disease, subjects should either be not treated with any approved treatments for AD or stabilized on approved medication(s) other than anti-Ab antibodies for the treatment of AD for at least 3 months prior to Baseline.
- Subject has a care partner who spends at least 15 hours/week with the subject, and can attend all visits with the subject, report accurately on the subject's status, and ensure compliance with all study requirements
- Subject and care partner must each independently be able to understand the study requirements and provide informed consent
Exclusion Criteria:
- Females who are not postmenopausal at Screening as defined by amenorrhea for at least 12 consecutive months or who have not been sterilized surgically (i.e. bilateral tubal ligation, total hysterectomy, or bilateral oophorectomy, all with surgery at least 1 month before Screening)
- Other than Alzheimer's disease, any neurologic or medical disorder which may impair cognition.
- Any contra-indication to undergo magnetic resonance imaging (MRI).
- Severe vision or hearing impairment that would prevent the subject from performing psychometric tests or otherwise complying with requirements for study participation and activities.
- History of certain neurological, psychiatric or medical conditions including autoimmune diseases.
- Clinically significant laboratory or electrocardiogram (ECG) abnormalities
- Presence of contraindication to lumbar puncture (LP) including taking anticoagulant or antiplatelet medications other than aspirin at a dose of < 100 mg/day or clopidogrel.
Taking any of the following medications.
- Immunosuppressant medications, including chronic systemic corticosteroids (chronic use of topical steroids is allowed)
- Injected or infused antibody therapies, including but not limited to antibodies directed against tumor necrosis factor (TNF), anti-interleukin-6 (anti-IL-6), natalizumab, rituximab and similar agents
- Aducanumab, (aducanumab-avwa) intravenous injection (brand name: Aduhelm™), or any other experimental or approved anti-amyloid antibody
- Insulin
- Anticoagulant or anti-platelet medications including warfarin, heparinoids and direct coagulation factor inhibitors (e.g. apixaban, dabigatran, rivaroxaban) within 90 days of the planned first dose of study drug; either aspirin at a dose of < 100 mg/day or clopidogrel at a dose of 75 mg/day, but not both in combination is permitted
- Participation in any other interventional clinical trial, or treatment with any investigational drug or investigational use of an approved therapy, within 30 days or 5 half-lives of such agent, whichever is longer, prior to the first Screening visit
- Subject currently smokes more than 5 cigarettes or equivalent tobacco consumption daily
- Regular nonmedical use of cannabis or cannabis products unless such products are documented by the manufacturer's label not to contain tetrahydrocannabinol or its derivatives or analogs
- History of drug (including cannabis) or alcohol abuse within the last 5 years
- Positive urine drug test for drugs of abuse at Screening. Subjects who test positive for benzodiazepines or opioids in urine drug testing need not be excluded if in the clinical opinion of the investigator, this is due to the subject taking prior/concomitant medications containing benzodiazepines or opioids for a medical condition and not due to drug abuse
- Subjects who answer "yes" to Columbia Suicidality Rating Scale (C-SSRS) suicidal ideation Type 4 or 5, or any suicidal behavior assessment within 6 months before Screening, at Screening, or has been hospitalized or treated for suicidal behavior in the past 5 years before Screening
- Unwillingness to comply with study requirements or history of noncompliance in prior clinical trials
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
IBC-Ab002 low dose or placebo
|
Normal Saline
An anti-PD-L1 monoclonal antibody
|
Experimental: Cohort 2
IBC-Ab002 mid low dose or placebo
|
Normal Saline
An anti-PD-L1 monoclonal antibody
|
Experimental: Cohort 3
IBC-Ab002 mid dose or placebo
|
Normal Saline
An anti-PD-L1 monoclonal antibody
|
Experimental: Cohort 4
IBC-Ab002 mid high dose or placebo
|
Normal Saline
An anti-PD-L1 monoclonal antibody
|
Experimental: Cohort 5
IBC-Ab002 high dose or placebo
|
Normal Saline
An anti-PD-L1 monoclonal antibody
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of subjects with adverse events, serious adverse events
Time Frame: 48 weeks
|
Safety Outcome
|
48 weeks
|
Incidence of subjects with clinically significant changes in hematology parameters
Time Frame: 48 weeks
|
Safety Outcome - complete blood count, white blood cells, red blood cells, platelets, hematocrit, mean corpuscular hemoglobin (MCH), neutrophiles percent, neutrophiles absolute, lymphocytes percent, lymphocytes absolute, monocytes percent, monocytes absolute, eosinophils percent, eosinophils absolute, basophils percent, basophils absolute, mean platelet volume
|
48 weeks
|
Incidence of subjects with clinically significant changes in biochemistry parameters
Time Frame: 48 weeks
|
Safety Outcome - sodium, potassium, calcium, phosphorus, glucose, alanine aminotransferase (ALT), aspartate transaminase (AST), lactate dehydrogenase (LDH), creatine kinase (CK), gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), bilirubin, creatine, albumin, total protein, amylase, total cholesterol, triglycerides, thyroid function tests (T3, T4, TSH), coagulation panel International normalized ratio (INR) and partial thromboplastin time (PTT).
|
48 weeks
|
Incidence of subjects with clinically significant changes in urinalysis parameters
Time Frame: 48 weeks
|
Safety Outcome - protein, nitrates, glucose, specific gravity, ketones, urobilinogen, bilirubin, pH, hemoglobin
|
48 weeks
|
Incidence of subjects with clinically significant changes in vital signs
Time Frame: 48 weeks
|
Safety outcome - weight, heart rate, respiratory rate, body temperature, systolic and diastolic blood pressure
|
48 weeks
|
Incidence of subjects with clinically significant changes in physical examination
Time Frame: 48 weeks
|
Safety Outcome
|
48 weeks
|
Incidence of subjects with clinically significant changes in electrocardiogram (EEG)
Time Frame: 48 weeks
|
Safety Outcome
|
48 weeks
|
Incidence of subjects with development of new abnormalities on brain MRI
Time Frame: 48 weeks
|
Safety Outcome - lacunar infarcts, territorial infarct, macroscopic hemorrhage, deep white matter lesions, cerebral contusion, encephalomalacia, infective lesion, aneurysm or vascular malformation, intraparenchymal tumor, meningioma or arachnoid cyst, inflammation, edema
|
48 weeks
|
Incidence of subjects with increased suicidality
Time Frame: 48 weeks
|
Safety Outcome - measured using Columbia Suicidality Rating Scale. Part 1 of the scale (Suicidal Ideation) is comprised of 5 yes/no questions with "yes" indicating suicidal ideation and "no" indicating no suicidal ideation. Part 2 of the scale (Intensity of Ideation) is comprised of 5 items which should be rated with respect to the most severe type if ideation (with 5 being the most severe intensity and 1 being the least intensity). Part 3 of thee scale (Suicidal Behavior) is comprised of 5 yes/no items with "yes" indicating suicidal behavior and "no" indicating no suicidal behavior. Part 4 of the scale (Actual Attempts) is comprised of 2 items which should be rated with respect to the most severe outcome of the suicide attempt (with the highest score indicating the most severe outcome and 0 indicating no harm). |
48 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IBC-Ab002 levels in serum.
Time Frame: Pre-dose and up to Day 84 post-dose
|
Pharmacokinetic Outcome - Area under the concentration-time curve from time zero to infinity, Area under the concentration-time curve from time zero to the time of the last measurable sample, maximum observed concentration, time to reach maximum observed concentration, terminal elimination half-life, clearance, volume of distribution,
|
Pre-dose and up to Day 84 post-dose
|
Number of subjects with positive serum anti-IBC-Ab002 antibodies
Time Frame: 48 weeks
|
Pharmacokinetic Outcome
|
48 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Catherine Mummery, MD, Dementia Research Centre, UCL, London
- Study Director: Tommaso Croese, MD, Immunobrain Checkpoint
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IBC-01-01
- 1R01AG071810-01 (U.S. NIH Grant/Contract)
- 2021-006580-19 (EudraCT Number)
- PTCG-20-701033 (Other Grant/Funding Number: Alzheimer's Association)
- U1111-1303-6922 (Other Identifier: Universal Trial Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsActive, not recruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States